Biomedical Engineering Reference
In-Depth Information
26. Heinemann S, et al. (1977) Modulation of acetylcholine recep-
tor by antibody against the receptor. Proc. Natl. Acad. Sci. USA
74(7), 3090-3094.
27. Lindstrom J, Einarson B. (1979) Antigenic modulation and
receptor loss in experimental autoimmune myasthenia gravis.
Muscle Nerve 2(3), 173-179.
28. Reiness CG, et al. (1978) Antibody to acetylcholine receptor
increases degradation of junctional and extrajunctional recep-
tors in adult muscle. Nature 274(5666), 68-70.
29. Keefe D, et al. (2009) A rapid, fluorescence-based assay for
detecting antigenic modulation of the acetylcholine receptor on
human cell lines. Cytometry B. Clin. Cytom. 76(3), 206-212.
30. Barchan D, et al. (1999) Antigen-specific modulation of
experimental myasthenia gravis: nasal tolerization with recom-
binant fragments of the human acetylcholine receptor alpha-
subunit. Proc. Natl. Acad. Sci. USA 96(14), 8086-8091.
31. Hossann M, et al. (2006) Novel immunotoxin: a fusion protein
consisting of gelonin and an acetylcholine receptor fragment as
a potential immunotherapeutic agent for the treatment of
Myasthenia gravis. Protein Expr. Purif. 46(1), 73-84.
32. Chang T, et al. Selective recognition and elimination of
nicotinic acetylcholine receptor-reactive B cells by a recom-
binant fusion protein AChR-Fc in myasthenia gravis in vitro.
J. Neuroimmunol. 227(1,2), 35-43.
33. Parise F, et al. (1999) Construction and in vitro functional
evaluation of a low-density lipoprotein receptor/transferrin
fusion protein as a therapeutic tool for familial hyper-
cholesterolemia. Hum. Gene. Ther. 10(7), 1219-1228.
34. Moreland LW, et al. (1997) Treatment of rheumatoid arthritis
with a recombinant human tumor necrosis factor receptor
(p75)-Fc fusion protein. N. Engl. J. Med. 337(3), 141-147.
35. Moreland LW, et al. (1997) Biologic agents for treating
rheumatoid arthritis. Concepts and progress. Arthritis Rheum.
40(3), 397-409.
36. Marsh DR, et al. (2002) Neutralizing intraspinal nerve growth
factor with a trkA-IgG fusion protein blocks the development
of autonomic dysreflexia in a clip-compression model of spinal
cord injury. J. Neurotrauma. 19(12), 1531-1541.
37. Meyuhas R, et al. (2009) Enhanced HIV-1 neutralization by a
CD4-VH3-IgG1 fusion protein. Biochem. Biophys. Res. Com-
mun. 386(2), 402-406.
38. Schapira K, et al. (2009) Fn14-Fc fusion protein regulates
atherosclerosis in ApoE-/- mice and inhibits macrophage lipid
uptake in vitro. Arterioscler. Thromb. Vasc. Biol. 29(12),
2021-2027.
39. Qian ZM, et al. (2002) Targeted drug delivery via the trans-
ferrin receptor-mediated endocytosis pathway. Pharmacol.
Rev. 54(4), 561-587.
40. Fritzer M, et al. (1996) Cytotoxic effects of a doxorubicin-
transferrin conjugate in multidrug-resistant KB cells. Biochem.
Pharmacol. 51(4), 489-493.
41. Lai BT, et al. (1998) Mechanism of action and spectrum of cell
lines sensitive to a doxorubicin-transferrin conjugate. Cancer
Chemother. Pharmacol. 41(2), 155-160.
42. Singh M, et al. (1998) Transferrin directed delivery of adria-
mycin to human cells. Anticancer Res. 18(3A) 1423-1427.
43. Laske DW, et al. (1994) Efficacy of direct intratumoral therapy
with targeted protein toxins for solid human gliomas in nude
mice. J. Neurosurg. 80(3), 520-526.
44. Bickel U, et al. (1993) Pharmacologic effects in vivo in brain
by vector-mediated peptide drug delivery. Proc. Natl. Acad.
Sci. USA 90(7), 2618-2622.
45. Pardridge WM, et al. (1998) Combined use of carboxyl-
directed protein pegylation and vector-mediated blood-brain
barrier drug delivery system optimizes brain uptake of brain-
derived neurotrophic factor following intravenous administra-
tion. Pharm. Res. 15(4), 576-582.
46. Cheng PW, (1996) Receptor ligand-facilitated gene transfer:
enhancement of liposome-mediated gene transfer and expres-
sion by transferrin. Hum. Gene Ther. 7(3), 275-282.
47. Simoes S, et al. (1999) Cationic liposomes as gene transfer
vectors: barriers to successful application in gene therapy.
Curr. Opin. Mol. Ther. 1(2), 147-157.
48. Simoes S, et al. (1998) Gene delivery by negatively charged
ternary complexes of DNA, cationic liposomes and transferrin
or fusigenic peptides. Gene Ther. 5(7), 955-964.
49. Psaridi-Linardaki L, et al. (2005) Specific immunoadsorption
of the autoantibodies from myasthenic patients using the
extracellular domain of the human muscle acetylcholine recep-
tor alpha-subunit. Development of an antigen-specific thera-
peutic strategy. J. Neuroimmunol. 159(1,2), 183-191.
Search WWH ::
Custom Search